Subendothelial retention of atherogenic lipoproteins in early atherosclerosis

被引:705
作者
Skålén, K
Gustafsson, M
Rydberg, EK
Hultén, LM
Wiklund, O
Innerarity, TL
Borén, J [1 ]
机构
[1] Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden
[2] Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nature00804
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Complications of atherosclerosis are the most common cause of death in Western societies(1). Among the many risk factors identified by epidemiological studies, only elevated levels of lipoproteins containing apolipoprotein (apo) B can drive the development of atherosclerosis in humans and experimental animals even in the absence of other risk factors(2). However, the mechanisms that lead to atherosclerosis are still poorly understood. We tested the hypothesis that the subendothelial retention of atherogenic apoB-containing lipoproteins is the initiating event in atherogenesis(3). The extracellular matrix of the subendothelium, particularly proteoglycans, is thought to play a major role in the retention of atherogenic lipoproteins(4). The interaction between atherogenic lipoproteins and proteoglycans involves an ionic interaction between basic amino acids in apoB100 and negatively charged sulphate groups on the proteoglycans(5). Here we present direct experimental evidence that the atherogenicity of apoB-containing low-density lipoproteins (LDL) is linked to their affinity for artery wall proteoglycans. Mice expressing proteoglycan-binding-defective LDL developed significantly less atherosclerosis than mice expressing wild-type control LDL. We conclude that subendothelial retention of apoB100-containing lipoprotein is an early step in atherogenesis.
引用
收藏
页码:750 / 754
页数:6
相关论文
共 28 条
[1]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[2]   Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100 [J].
Borén, J ;
Lee, I ;
Zhu, WM ;
Arnold, K ;
Taylor, S ;
Innerarity, TL .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (05) :1084-1093
[3]   Identification of the principal proteoglycan-binding site in LDL -: A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding [J].
Borén, J ;
Olin, K ;
Lee, I ;
Chait, A ;
Wight, TN ;
Innerarity, TL .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (12) :2658-2664
[4]  
BRISSETTE L, 1986, J BIOL CHEM, V261, P1631
[5]   IDENTIFICATION OF APO-B-100 SEGMENTS MEDIATING THE INTERACTION OF LOW-DENSITY LIPOPROTEINS WITH ARTERIAL PROTEOGLYCANS [J].
CAMEJO, G ;
OLOFSSON, SO ;
LOPEZ, F ;
CARLSSON, P ;
BONDJERS, G .
ARTERIOSCLEROSIS, 1988, 8 (04) :368-377
[6]   Atherosclerosis: The road ahead [J].
Glass, CK ;
Witztum, JL .
CELL, 2001, 104 (04) :503-516
[7]  
GOLDMAN MH, 1998, ADV TISSUE BANKING, V2, P273
[8]   ISOLATION AND CHARACTERIZATION OF 4 HEPARIN-BINDING CYANOGEN-BROMIDE PEPTIDES OF HUMAN-PLASMA APOLIPOPROTEIN-B [J].
HIROSE, N ;
BLANKENSHIP, DT ;
KRIVANEK, MA ;
JACKSON, RL ;
CARDIN, AD .
BIOCHEMISTRY, 1987, 26 (17) :5505-5512
[9]   EFFECT OF ARTERIAL PROTEOGLYCANS AND GLYCOSAMINOGLYCANS ON LOW-DENSITY-LIPOPROTEIN OXIDATION AND ITS UPTAKE BY HUMAN MACROPHAGES AND ARTERIAL SMOOTH-MUSCLE CELLS [J].
HURTCAMEJO, E ;
CAMEJO, G ;
ROSENGREN, B ;
LOPEZ, F ;
AHLSTROM, C ;
FAGER, G ;
BONDJERS, G .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (05) :569-583
[10]   Differential cellular accumulation retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans - Apolipoproteins E3 and E2 greater than E4 [J].
Ji, ZS ;
Pitas, RE ;
Mahley, RW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (22) :13452-13460